Hans Kaanders PhD MD

Phase-III Randomized ARCON Trial: Comment from Hans Kaanders

BARCELONA—The finding from the phase-III ARCON trial presented at the 3rd ESTRO Forum that: Accelerated radiotherapy with carbogen and nicotinamide (ARCON) significantly improved outcomes for patients with advanced laryngeal cancer, was discussed with Oncology Times reporter Sarah Maxwell by Hans Kaanders PhD MD, from Radboud University Medical Centre.

Further reading